SUBSCRIBE NOW
Join our
subscribers!
LATEST PSYCHEDELICS STOCKS NEWS
90 views5 min read
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Ltd.First subject enrolled and initial top-line results expected in Q3-2023TORONTO, March 28, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disor... Read More...
94 views4 min read
Numinus Launches the Practitioner Certification Pathway
VANCOUVER, BC, March 27, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") tr... Read More...
116 views8 min read
Red Light Holland and Mera Life Sciences Terminate Agreement in St. Vincent and the Grenadines
Toronto, Ontario--(Newsfile Corp. - March 23, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the l... Read More...
Psyence Group Announces Cantheon Capital Private Placement
<!-- Name:DistributionId Value:8793631 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:500076928 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:b4d5419e-e2a1-4696-828f-4b7a308c0152 -->
VANCOUVER, B... Read More...
35 views6 min read
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its e... Read More...
27 views4 min read
Field Trip Health & Wellness Obtains CCAA Protection
<!-- Name:DistributionId Value:8793689 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->
<!-- Name:CustomerId Value:1262670 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:150a0924-2718-4193-bef6-649624065f26 -->
TORONTO, March 22,... Read More...
330 views4 min read
Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
<!-- Name:DistributionId Value:8792198 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:1216524 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:aaff81f9-2cd9-4612-9320-0dc7a764f4ff -->
VANCOUVER, Bri... Read More...
Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
VANCOUVER, BC, March 22, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday... Read More...
Red Light Holland Looking Forward to AGSM, Including Corporate Update from Chairman Brad J Lamb and a Live Q&A With CEO Todd Shapiro on March 23rd at 11 AM
Brad J Lamb, Red Light Holland's Chairman of the Board will Chair the AGSM, which takes place at 11 am EST on March 23, 2023CEO Todd Shapiro, CTIO Sarah Hashkes and CFO David Ascott of Red Light Holland will conduct a live Q&A immediately after the AGSMThe AGSM will take place in person at the offices of the Company located at 1 Adela... Read More...
Psyence Partners with iNGENĹ« for Palliative Care Clinical Trial in Australia
<!-- Name:DistributionId Value:8791770 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:500076928 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:10aca96b-f59f-487f-865f-909c178712e5 -->
VANCOUVER, B... Read More...
1258 views6 min read
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
<!-- Name:DistributionId Value:8791499 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->
<!-- Name:CustomerId Value:1105448 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:deec8a42-4c9a-48fd-841f-1af92b8b93ba -->
TORONTO, March... Read More...
54 views4 min read
Field Trip Health & Wellness to Close Clinics in 5 Locations
<!-- Name:DistributionId Value:8788902 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->
<!-- Name:CustomerId Value:1262670 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:97033991-d011-46e0-917f-9b83e290356e -->
TORONTO, March 15,... Read More...
705 views2 min read
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
<!-- Name:DistributionId Value:8788550 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:3763 -->
<!-- Name:CustomerId Value:500069339 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:1d0218f7-ea1d-4495-8ef2-1d5e7fc95797 -->
ENGLEWOOD CL... Read More...
CORRECTION — BetterLife Closes $1,857,143 of Private Placement
<!-- Name:DistributionId Value:8788199 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:1216524 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:bd1697f1-abe1-4c61-a2c0-2e14e2ec4bdb -->
NOT FOR DISTRI... Read More...
121 views7 min read
Chaga Mushroom Market to Garner $1.4 Billion by 2031 : Allied Market Research
<!-- Name:DistributionId Value:8788016 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:5557 -->
<!-- Name:CustomerId Value:1098508 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:8e73f3cf-4d86-4c4b-87cd-a41d9d8c6e64 -->
Portland, OR, ... Read More...
44 views7 min read
Red Light Holland Announces Distribution Agreement With New Zealand Based NUBU Pharmaceuticals To Explore Legal Import and Distribution Of Psilocybin Microdosing Capsules To Australasia
Toronto, Ontario--(Newsfile Corp. - March 13, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreationa... Read More...
1206 views5 min read
BetterLife Files Amended and Restated Offering Document for Offering of Units
<!-- Name:DistributionId Value:8786324 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:1216524 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:ce3904d8-3cfb-42c9-b967-a3c8a9057f80 -->
NOT FOR DISTRI... Read More...
1135 views6 min read
BetterLife Announces Pricing of Proposed Offering of Units
<!-- Name:DistributionId Value:8784421 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:1216524 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:bdd13353-e747-4178-82b8-455ce1716dbf -->
NOT FOR DISTRI... Read More...
113 views5 min read
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
<!-- Name:DistributionId Value:8784103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->
<!-- Name:CustomerId Value:1105448 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:863e347a-d4b8-40b3-aef2-cadd80329520 -->
FDA recommends... Read More...
1327 views5 min read
BetterLife Announces Offering of Units
<!-- Name:DistributionId Value:8783646 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->
<!-- Name:CustomerId Value:1216524 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:2b7cca25-ad23-435f-b4ab-5d49209e3a38 -->
NOT FOR DISTRI... Read More...
41 views8 min read
Red Light Holland’s Psilocybin Truffles Arrive Successfully in Canada, Under a Health Canada Approved Psilocybin Import Permit to CCrest Labs, Beginning Development of Microdosing Capsules
Red Light Holland safely exports another 3000 Grams (3KG) of Psilocybin Truffles, produced and sold in The Netherlands, into Canada under a fourth Health Canada approved psilocybin import permit to its laboratory partner, CCrest Laboratories Inc., a cGMP pharmaceutical laboratory in Montreal, CanadaCCrest Labs to utilize its newly amended... Read More...
872 views9 min read
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
Optimi Health Corp.The announcement follows a national reclassification of MDMA and psilocybin for therapeutic uses in Australia as a result of the years-long effort of Mind Medicine Australia and its dedicated supportersHighlights:Â Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-t... Read More...
904 views6 min read
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered ... Read More...
1096 views8 min read
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia ---- Company has transitioned from a discovery to a development organization –-- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 --VANCOUVER, British Columbi... Read More...
476 views8 min read
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
- CYB003 Phase 1/2a interim data demonstrate rapid and short-acting effects; robust psychedelic effects at low doses; positive safety and tolerability profile; top-line efficacy data expected late Q3 2023 -- Initial findings from Phase 1 CYB004-E study suggest IV DMT was well-tolerated; study design expanded to accelerate first-in-human d... Read More...
Field Trip Health & Wellness Provides Business Update and Reports Fiscal Third Quarter 2023 Results
<!-- Name:DistributionId Value:8778835 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->
<!-- Name:CustomerId Value:1262670 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:7b188cbe-d9c3-42e3-800d-505ddd73a542 -->
TORONTO, Feb. 28, ... Read More...
48 views0 min read
Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT
Vancouver --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.Moreau told Pro... Read More...
Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
VANCOUVER, BC, Feb. 24, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Ch... Read More...
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
- Company to provide CYB003 Phase 1/2a interim study readout and update on its CYB004 program at upcoming R&D Day on February 28, 2023 -This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplement dated August 8, 2022 to its short form base shelf prospectus dated July 5, 2021TORONTO, Febr... Read More...
1366 views2 min read
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
<!-- Name:DistributionId Value:8747816 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:3763 -->
<!-- Name:CustomerId Value:500069339 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:501d319d-883b-47e1-8bbf-182b717a193c -->
Patent appli... Read More...
857 views4 min read
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,... Read More...
876 views3 min read
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
<!-- Name:DistributionId Value:8745619 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->
<!-- Name:CustomerId Value:1215554 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:15d9ac77-e32d-4c3e-8cc8-486c808a7e18 -->
VANCOUVER, Bri... Read More...
1241 views5 min read
Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision
The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditionsNEDLANDS, Australia, Feb. 8, 2023 -- Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Scie... Read More...
941 views4 min read
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
PharmAla BiotechPharmAla Biotech will provide MDMA to Revive Therapeutics in their development of an MDMA Microneedle PatchVANCOUVER, British Columbia, Feb. 06, 2023 -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDM... Read More...
28 views5 min read
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
Revive Therapeutics Ltd.TORONTO, Feb. 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a supply agreement wit... Read More...
75 views0 min read
Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study
Vancouver, BC --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducte... Read More...
1363 views6 min read
Field Trip Health & Wellness Announces Posting on the OTC Market
<!-- Name:DistributionId Value:8742185 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->
<!-- Name:CustomerId Value:1262670 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:36d88576-aa96-435c-82a4-623095aabbff -->
TORONTO, Feb. 03, ... Read More...
1371 views5 min read
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
<!-- Name:DistributionId Value:8742224 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->
<!-- Name:CustomerId Value:1105448 -->
<!-- Name:HasMediaSnippet Value:false -->
<!-- Name:AnalyticsTrackingId Value:eae14e8b-e8d8-422d-8996-835fd7a7e697 -->
TORONTO, Feb. ... Read More...
819 views3 min read
Silo Pharma Announces Expansion of Intellectual Property Portfolio
Silo Pharma, Inc.Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective DisordersENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedeli... Read More...
418 views7 min read
Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Clinical trial will be the first to test whole Psilocybe mushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy.
Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will ... Read More...
Make smarter
investment strategies
with in-depth news reports
Join our subscribers!
By subscribing, you agree to our
Terms and Conditions
We don't spam and we promise to never share your information.